# Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis

> **NCT06058156** · PHASE2 · TERMINATED · sponsor: **Sanofi** · enrollment: 70 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** SAR444656 (KT-474)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06058156
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-11-09
- **Primary completion:** 2025-10-23
- **Final completion:** 2025-11-20
- **Target enrollment:** 70 (ACTUAL)
- **Why stopped:** Sponsor decision. Not related to safety concern.
- **Last updated:** 2025-12-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06058156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06058156, "Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06058156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*